STX16

Across TCGA pan-cancer cohorts, STX16 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STX16 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher STX16 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated STX16 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where STX16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.711	0.945	<.001	34	view →
PDAC	OS	Tertile	III,IV	0.984	0.382	.001	31	view →
CCRCC	DFS	Median	All	1.000	0.868	.004	16	view →
UCEC	DFS	Tertile	III,IV	1.000	0.279	.027	14	view →
LUAD	OS	Median	II,III,IV	0.440	0.806	.013	5	view →
HNSC	OS	Quartile	All	0.963	0.889	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STX16–LSCC (OS)

Open the LSCC breakdown →